Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $150,976.40 in Stock

Key Points

• Soleil Boughton, an insider at Hims & Hers Health, sold 2,572 shares of stock for approximately $150,976 on July 28, reducing their ownership by 1.63%.
• Hims & Hers Health's stock is currently valued at $60.29 after a 2.8% increase, with a market cap of $13.50 billion and a 12-month high of $72.98.
• The company reported a significant 110.7% increase in revenue year-over-year for the last quarter, totaling $586.01 million, and an EPS of $0.20, surpassing analyst expectations.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $58.70, for a total transaction of $150,976.40. Following the completion of the sale, the insider directly owned 155,593 shares of the company's stock, valued at $9,133,309.10. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, July 14th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.82, for a total transaction of $122,993.04.
• On Monday, June 30th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.50, for a total transaction of $129,886.00.
• On Tuesday, June 17th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $59.75, for a total value of $153,677.00.
• On Monday, June 16th, Soleil Boughton sold 5,451 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.80, for a total value of $309,616.80.
• On Tuesday, May 27th, Soleil Boughton sold 3,233 shares of Hims & Hers Health stock. The stock was sold at an average price of $55.87, for a total value of $180,627.71.

Hims & Hers Health Stock Up 2.8%

Shares of Hims & Hers Health stock traded up $1.61 on Tuesday, hitting $60.29. 35,546,038 shares of the company traded hands, compared to its average volume of 33,722,180. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company has a market cap of $13.50 billion, a PE ratio of 87.38, a PEG ratio of 2.13 and a beta of 2.02. The company has a 50-day moving average price of $53.08 and a 200 day moving average price of $43.24.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the previous year, the company posted $0.05 earnings per share. The business's quarterly revenue was up 110.7% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in the company. Webster Bank N. A. grew its position in Hims & Hers Health by 229.1% in the second quarter. Webster Bank N. A. now owns 905 shares of the company's stock worth $45,000 after acquiring an additional 630 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the 1st quarter valued at $30,000. Parallel Advisors LLC boosted its holdings in Hims & Hers Health by 175.0% in the second quarter. Parallel Advisors LLC now owns 1,155 shares of the company's stock worth $58,000 after purchasing an additional 735 shares in the last quarter. UMB Bank n.a. increased its position in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after buying an additional 933 shares during the last quarter. Finally, AdvisorNet Financial Inc raised its holdings in Hims & Hers Health by 127.1% during the second quarter. AdvisorNet Financial Inc now owns 1,340 shares of the company's stock valued at $67,000 after buying an additional 750 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on HIMS shares. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. Truist Financial upped their price objective on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Bank of America boosted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and an average price target of $39.83.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.